医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Cytori Partner Kerastem Expands US Phase II Trial for Early Stage Hair Loss

2016年01月21日 PM09:00
このエントリーをはてなブックマークに追加


 

SAN DIEGO & TOKYO

Cytori Therapeutics, Inc. (NASDAQ: CYTX) announced today that its licensee Kerastem Technologies, LLC, has expanded STYLE, its US phase II clinical trial investigating early stage female and male pattern hair loss. In this expansion, Kerastem has added new trial sites in New York and New Jersey to complement the currently enrolling sites in Los Angeles and Miami.

“Kerastem is dedicated to bringing Cytori technology to market for men and women with alopecia,” said Dr. Marc H. Hedrick, President & CEO of Cytori. “The Kerastem team has assembled an excellent clinical team. If this trial is successful, we believe the Kerastem/Cytori partnership could provide effective treatment for people dealing with hair loss and create a significant new revenue source for Cytori, creating value for our stockholders.”

STYLE is a phase II randomized, blinded, and controlled investigation of Kerastem therapy in early stage female and male pattern baldness. STYLE is approved to enroll up to 70 patients at up to eight (8) centers within the United States.

Outside of the United States, Kerastem is actively involved in market development, with Kerastem therapy currently being offered at a number of clinics in Europe & Japan.

To learn more about Kerastem or the STYLE Clinical Trial, please visit www.kerastem.com or https://clinicaltrials.gov/ct2/show/NCT02503852?term=Kerastem&rank=1

About Cytori

Cytori Therapeutics is a late stage cell therapy company developing autologous cell therapies from adipose tissue to treat a variety of medical conditions. Data from preclinical studies and clinical trials suggest that Cytori Cell Therapy™ acts principally by improving blood flow, modulating the immune system, and facilitating wound repair. As a result, Cytori Cell Therapy™ may provide benefits across multiple disease states and can be made available to the physician and patient at the point-of-care through Cytori’s proprietary technologies and products. For more information visit www.cytori.com.

About Kerastem

Kerastem Technologies, LLC is a private company owned by Bimini Technologies, and holds global rights to commercialize Cytori Cell Therapy for alopecia and hair related indications. The Bimini portfolio of products also includes Puregraft, the world’s leading fat grafting solution.

Cautionary Statement Regarding Forward-Looking Statements

This press release includes forward-looking statements regarding events, trends and business prospects, which may affect our future operating results and financial position. Such statements, including, without limitation, potential benefits to Cytori and its stockholders of successful clinical trials and the positive effects of such trials on Cytori’s partnerships, are all subject to risks and uncertainties that could cause our actual results and financial position to differ materially. Some of these risks and uncertainties include, but are not limited to, inherent risk and uncertainty in the protection intellectual property rights, regulatory uncertainties, risks in the conduct of clinical trials, risks in the collection and results of clinical data, final clinical outcomes, dependence on third party performance, performance and acceptance of our products in the marketplace, as well as other risks and uncertainties described under the heading “Risk Factors” in Cytori’s Securities and Exchange Commission Filings on Form 10-K and Form 10-Q. We assume no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160121005249/en/

CONTACT

Cytori Therapeutics, Inc.
Tiago Girao, +1 (858) 458.0900
ir@cytori.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • CANbridge Life Sciences Receives Approval to Commence CAN017 Ib/III Trial in Esophageal Squamous Cell Cancer (ESCC) In China
  • AVEO Announces Acceptance of CANbridge Investigational New Drug Application for CAN017 (AV-203) Trial in Esophageal Squamous Cell Cancer (ESCC) in China
  • STAAR Surgical and Shinjuku LASIK Clinic in Japan Announce Strategic Cooperation Agreement
  • 新研究调查诊断性多通道睡眠检查之前采用Masimo SET®脉搏氧饱和度仪居家监测筛查唐氏综合征患儿罹患阻塞性睡眠呼吸暂停的风险
  • ダウン症候群の小児を対象とする睡眠時障害診断のマルチチャンネル研究に先立つ閉塞性睡眠時無呼吸症リスクのスクリーニングとしてMasimo SET®パルスオキシメトリーを使用するホームモニタリングの有用性を検討する新研究